Company Description
Alumis' mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.
We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis, and is currently being evaluated in additional Phase 2 clinical trials in patients with systemic lupus erythematosus (SLE) and non-infectious uveitis, for which we expect to report results in 2026 and by the end of 2024, respectively.
With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication.
TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases.
In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024.
| Country | United States |
| Founded | 2021 |
| IPO Date | Jun 28, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 107 |
| CEO | Martin Babler |
Contact Details
Address: 280 East Grand Avenue South San Francisco, CA 94080 United States | |
| Phone | (650) 231-6625 |
| Website | alumis.com |
Stock Details
| Ticker Symbol | ALMS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001847367 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Martin Babler | President and Chief Executive Officer, Chairman |
| Mark Bradley | Chief Development Officer |
| Jörn Drappa, M.D., Ph.D. | Chief Medical Officer |
| David M. Goldstein, Ph.D. | Chief Scientific Officer |
| Roy Hardiman | Chief Business and Legal Officer |
| John Schroer | Chief Financial Officer |
| Sara Klein | General Counsel |
| Derrick Richardson | Senior Vice President of People and Culture |
| Alan B. Colowick, M.D., M.P.H. | Director |
| Sapna Srivastava, Ph.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 1, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jul 1, 2024 | 8-K | Current Report |
| Jun 28, 2024 | 424B4 | Prospectus |
| Jun 28, 2024 | FWP | Free Writing Prospectus |
| Jun 27, 2024 | EFFECT | Notice of Effectiveness |
| Jun 27, 2024 | CERT | Certification by an exchange approving securities for listing |
| Jun 25, 2024 | 8-A12B | Registration of securities |
| Jun 24, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 18, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 7, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |